Science & Research
Blood Donor Shortage Worsens as Artificial Substitutes Remain Limited to Emergency Use
A critical shortage of blood donors, particularly those with universal O-negative type, persists due to declining participation and demographic shifts, while artificial blood substitutes like ErythroMer remain years away from replacing human donations for most medical needs.
Study Reveals Declining Heart Health Among Older Adults with Cardiovascular Conditions
New research shows significant declines in cardiovascular health among U.S. adults aged 65 and older with high blood pressure, stroke, or heart failure, highlighting critical gaps in blood pressure control and physical activity.
Incannex Healthcare's IHL-42X Shows Promising Phase 2 Results for Sleep Apnea Treatment
Incannex Healthcare Inc. reports significant progress with its IHL-42X treatment for obstructive sleep apnea, achieving up to 83% reduction in apnea events with strong patient-reported outcomes, positioning the company for potential market entry while strengthening its financial position.
Branded Legacy Subsidiary Partners with McMaster University to Evaluate Addiction Treatment Solutions
Branded Legacy's subsidiary Bio-Legacy Evaluative Group has formed a strategic partnership with McMaster University to advance rigorous evaluations and clinical trials for addiction interventions, aiming to reduce overdose deaths and promote recovery.
Erica Ollmann Saphire Honored with 2025 San Diego Genius Award for Pioneering Immunology Research
Dr. Erica Ollmann Saphire, a leading figure in immunology research, is set to receive the 2025 San Diego Genius Award for her groundbreaking work on viral infections and immune system responses, highlighting the intersection of science and community enrichment.
BioMed X and Novo Nordisk Collaborate to Revolutionize Oral Peptide Drug Delivery
BioMed X and Novo Nordisk have partnered to tackle the challenge of oral peptide drug delivery, aiming to improve patient compliance and treatment efficacy through innovative formulation technologies.
Safe Pro Group Expands Global Patent Protections for AI-Powered Explosives Detection Technology
Safe Pro Group advances its intellectual property strategy with international patent protections for its AI-powered explosives detection systems, enhancing its position in defense and humanitarian demining markets.
Ascentage Pharma Advances Global Phase III Trial for Lisaftoclax in Higher-Risk MDS Treatment
Ascentage Pharma's GLORA-4 Phase III trial of lisaftoclax, a potential breakthrough for higher-risk myelodysplastic syndrome (MDS), receives FDA and EMA clearance, marking a significant step towards addressing a critical unmet medical need in oncology.
University of Rochester Researchers Develop Novel Material to Enhance Solar Energy Generation
A breakthrough in solar thermoelectric generators (STEGs) by University of Rochester researchers promises to significantly boost efficiency and energy generation, potentially impacting companies like PowerBank Corporation.
Soligenix Inc. Receives FDA Orphan Drug Designation for Dusquetide in Behçet’s Disease
Soligenix Inc. has been granted FDA orphan drug designation for dusquetide, a significant step forward in treating Behçet’s Disease, highlighting the potential for new therapies in rare diseases.
GeoVax to Showcase Mpox Vaccine Progress at Emerging Growth Conference
GeoVax Labs, Inc. will present updates on its GEO-MVA Mpox vaccine development at the Emerging Growth Conference, highlighting potential regulatory acceleration and manufacturing advantages.
Creative Biolabs Advances Antibody Non-GMP Production and Quality Control
Creative Biolabs is addressing the critical need for high-quality, research-grade antibodies and specialized quality control services in the therapeutic antibody development sector.
IndyGeneUS Bio Wins National Recognition for Inclusive Genomics Research
IndyGeneUS Bio, a Baltimore-based life sciences startup, has been awarded first place in the Disabled American Veterans Pitch Competition for its efforts to make genomic research more inclusive for underserved populations.
Everyday Strategies to Enhance Brain Health and Cognitive Function
Exploring simple, effective methods to maintain and improve brain health through mental stimulation, diet, mental wellness, and physical activity.
Simulated Environment Concepts Announces Breakthrough in Livestock Production with Structured Water Technology
Simulated Environment Concepts, Inc. reveals promising results from a trial using structured water in cattle, indicating potential to revolutionize livestock production amidst industry challenges.
Study Reveals B-Vitamin Supplements Could Offer New Hope for Parkinson’s Disease Patients
A recent study highlights the potential of B-vitamin supplements in addressing some medical needs of Parkinson’s disease patients, suggesting a simple yet effective treatment option.
Clene Inc. to Share Corporate Update at Emerging Growth Conference
Clene Inc. is set to present a corporate update at the Emerging Growth Conference, highlighting its progress in developing treatments for neurodegenerative diseases.
Japan Achieves Milestone with First Domestically Made Quantum Computer
Japan's unveiling of a domestically produced quantum computer signifies a major advancement in the country's technology sector and its ambitions in the global quantum computing race.
Creative Biolabs Enhances Gene Therapy Research with Expanded Liposomal Drug Delivery Services
Creative Biolabs has expanded its liposomal drug delivery services to support advancements in gene therapy, oncology, and molecular medicine, offering customized solutions for research institutions and pharmaceutical industries worldwide.
Cybin Inc. Advances Mental Health Treatments with Q1 2025 Results and Key Program Updates
Cybin Inc. reports significant progress in its Phase 3 depression program and Phase 2 anxiety study, highlighting advancements in next-generation mental health treatments.
Clene Inc. Advances Toward FDA Submission for ALS Therapy with Promising Q2 2025 Results
Clene Inc. reports significant progress in its Q2 2025 results, targeting a year-end NDA submission for its ALS therapy, CNM-Au8, with sufficient cash runway into Q1 2026.
Intensity Therapeutics Pioneers New Cancer Treatment with Minimal Side Effects
Intensity Therapeutics is advancing a novel cancer treatment that directly targets tumors with minimal side effects, offering hope for patients with refractory solid tumors.
Understanding the Risks and Treatments of Benign Brain Tumors in Women
This article highlights the increased risk of benign brain tumors in women and the importance of recognizing early symptoms, while also discussing current treatment options and ongoing research efforts.
New High Blood Pressure Guideline Focuses on Prevention and Early Treatment to Combat CVD Risk
A joint guideline by the American Heart Association and the American College of Cardiology emphasizes early treatment and lifestyle changes to manage high blood pressure, aiming to reduce the risk of cardiovascular diseases and cognitive decline.
Maryland's Research Sector at Risk as Federal Funding Cuts Loom
The article explores the potential economic and scientific repercussions of federal funding cuts on Maryland's research institutions and biotech industry, highlighting the urgent need for state intervention.
New Satellite Orbit Determination Method Enhances Navigation Precision for Mega-Constellations
A breakthrough in satellite precise orbit determination method significantly improves navigation accuracy for future mega-constellations by reducing reliance on ground stations and correcting systematic rotation errors.
Revolutionary Hydrogel Cubes Offer New Frontier in Dynamic Data Storage
Researchers have developed a LEGO-like hydrogel system capable of storing over 800 billion data configurations, revolutionizing dynamic data storage and secure encoding.
Glidelogic Corp. Launches Advanced AI-Powered ResearchMind Platform Globally
Glidelogic Corp. has globally launched its upgraded ResearchMind platform, integrating advanced AI technologies to enhance academic research and hypothesis formation.
CNS Pharmaceuticals Inc. Advances TPI 287 Toward Phase 2 GBM Trial Amid Improved Financials
CNS Pharmaceuticals Inc. reports a slight improvement in Q2 2025 financials, with reduced net losses and increased R&D expenses as it prepares for a Phase 2 trial of TPI 287 for glioblastoma multiforme, highlighting the drug's potential to cross the blood-brain barrier and treat CNS tumors.
New Study Challenges Traditional Psoriasis Severity Classifications
Recent research indicates that psoriasis affecting less than 3% of body surface area may still impose a significant disease burden, prompting a reevaluation of current treatment approaches.